A brief post raises a possible link between GLP-1 medications and lower odds of age-related macular degeneration in people with diabetes. No study details given.
Recap by typeshit. Post by Facebook on Facebook.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
New real-world data compares two paths for cardiovascular outcomes: stepping up the semaglutide dose or moving patients over to tirzepatide.
The rheumatologist points to NEJM results reporting up to 25% weight reduction on retatrutide, with subanalyses showing less knee osteoarthritis pain.
Loading…